life
Article

Comparison of Data Mining Methods for the Signal
Detection of Adverse Drug Events with a Hierarchical
Structure in Postmarketing Surveillance
Goeun Park â€  , Heesun Jung â€  , Seok-Jae Heo â€ 

and Inkyung Jung *

Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine,
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea; gogoeun@yuhs.ac (G.P.); 6549209@naver.com (H.J.);
sjheo@yuhs.ac (S.J.H.)
* Correspondence: ijung@yuhs.ac; Tel.: +82-2-2228-2494; Fax: +82-2-2227-8308
â€  These authors contributed equally to this work.
Received: 29 May 2020; Accepted: 4 August 2020; Published: 5 August 2020




Abstract: There are several different proposed data mining methods for the postmarketing surveillance
of drug safety. Adverse events are often classified into a hierarchical structure. Our objective was to
compare the performance of several of these different data mining methods for adverse drug events
data with a hierarchical structure. We generated datasets based on the World Health Organizationâ€™s
Adverse Reaction Terminology (WHO-ART) hierarchical structure. We evaluated different data
mining methods for signal detection, including several frequentist methods such as reporting odds
ratio (ROR), proportional reporting ratio (PRR), information component (IC), the likelihood ratio
test-based method (LRT), and Bayesian methods such as gamma Poisson shrinker (GPS), Bayesian
confidence propagating neural network (BCPNN), the new IC method, and the simplified Bayesian
method (sB), as well as the tree-based scan statistic through an extensive simulation study. We also
applied the methods to real data on two diabetes drugs, voglibose and acarbose, from the Korea
Adverse event reporting system. Only the tree-based scan statistic method maintained the type I
error rate at the desired level. Likelihood ratio test-based methods and Bayesian methods tended
to be more conservative than other methods in the simulation study and detected fewer signals in
the real data example. No method was superior to the others in terms of the statistical power and
sensitivity of detecting true signals. It is recommended that those conducting drug-adverse event
surveillance use not just one method, but make a decision based on several methods.
Keywords: disproportionate reporting rate; drug safety surveillance; pharmacoepidemiology;
spontaneous reporting system; tree-based scan statistic

1. Introduction
It is critical to detect signals of adverse drug reactions from real-world data early enough to protect
public health. From the real-world data, we could identify new effects of drugs that had not been
identified during premarketing clinical trials. Adverse event (AE) information after drug marketing is
often collected via a spontaneous reporting system to identify any long-term adverse drug reactions.
In Korea, for example, the Korea Institute of Drug Safety and Risk Management (www.drugsafe.or.kr)
collects the information through a spontaneous reporting system.
Through this system, anyone, for example, a patient who has taken the drug, a doctor, or the
manufacturer, can report an AE. They report information such as the symptoms of the AE, the date of
onset, the name of the drug, the frequency and duration of the dose, patient information, and causality
assessment information. As the causality can only be reported by medical experts, the information

Life 2020, 10, 138; doi:10.3390/life10080138

www.mdpi.com/journal/life

Life 2020, 10, 138

2 of 21

reported by the patients does not confirm that an AE has been caused by a particular drug. In addition,
there could be issues related to data quality and under-reporting. The total number of people who
received the drug and the number of AEs are not precisely known. It is difficult to determine a causal
relationship between drugs and adverse effects from a spontaneous reporting system database. We can
only identify signals of adverse drug reactions, so additional in-depth studies are needed [1].
Statistical analysis is performed to detect whether any particular AEs have occurred more frequently
or whether there are any unexpected AEs. Among the various data mining tools, disproportionality
methods are widely used for AE signal detection. Different disproportionality methods exist based on
different measures such as the reporting odds ratio (ROR) [2], proportional reporting ratio (PRR) [3],
information component (IC), likelihood ratio test-based method (LRT) [4], gamma Poisson shrinker
(GPS) [5], Bayesian confidence propagating neural network (BCPNN) [6], new IC method [7,8], and the
simplified Bayesian method (sB) [9]. ROR, PRR, IC, and LRT are frequentist methods, while GPS,
BCPNN, the new IC method, and sB are Bayesian methods [10]. Some studies suggest that Bayesian
methods, such as multi-item gamma Poisson shrinker (MGPS) and BCPNN, outperform frequentist
methods such as PRR [2,3,6,7,11]. Other studies showed that the sB method performed better than
BCPNN and PRR [9,11]. Unlike other methods, the GPS method needs to estimate hyperparameters
of the prior distribution using the whole data. Because of this process, the GPS method requires
more computation time. Thus, most pharmaceutical companies and national and international
pharmacovigilance organizations use other methods more often than the GPS method [12].
Another type of data mining method for signal detection is the tree-based scan statistic (TreeScan)
proposed by Kulldorff et al. [13]. This method simultaneously searches for signals at any level (or
layer) of AE in a hierarchical structure, adjusting for the multiple testing problem. It has been applied
to drug safety surveillance as well as occupational disease surveillance [13,14].
Both LRT and TreeScan methods were developed based on a likelihood ratio test with the test
statistic as the maximum likelihood ratio. Moreover, both methods use the Monte Carlo method to
obtain the empirical distribution for statistical inference. The LRT method can handle AEs such as
system-organ classes (SOC), preferred terms (PT), or included terms (IT) (only one layer, not all the
layers together). If the AE is coded as PT, the LRT method detects the signal of single PT. The TreeScan
method for detecting AE signals for a fixed drug in data with multiple layers may consider all the
layers, and search for signals of PT and SOC (or other layers) together. The LRT method is more general
and covers different aspects of safety signal detection. The TreeScan method is for detecting AE or
certain prespecified AE groups as signals for a fixed drug, which is a special case of the LRT method.
Clinical information related to adverse drug reactions is generally coded using medical dictionaries
such as the World Health Organization Adverse Reaction Terminology (WHO-ART) and the Medical
Dictionary for Regulatory Activities (MedDRA), which have a hierarchical structure. There are several
studies comparing the performance of disproportionality methods in a usual database format with
AEs and drug combination data [2,3,6,7,9,11,12,15]. However, it is not clear which method performs
better than the others when AEs are classified into a hierarchical structure. There is a study comparing
the application of the GPS and TreeScan methods to real cohort data by Brown et al. [15]. They showed
that the signaled regions were similar. However, in some cases, the TreeScan method detected signals
that were not detected by the GPS. We do not know which results are more reliable.
The purpose of this study was to compare the performance of several different data mining
methods for signal detection in adverse drug event data grouped into hierarchical structures. Through
an extensive simulation study, we evaluated the performance of ROR, PRR, IC, LRT, GPS, BCPNN,
sB, and TreeScan on datasets generated based on the WHO-ARTâ€™s hierarchical structure. Originally,
the methods except TreeScan were not developed for hierarchically structured data. We evaluated
all the methods by considering all layers, instead of limiting to a single layer, to better reflect the
hierarchical data structure and make fair comparisons. We used the type I error rate, power, sensitivity,
and positive predictive value as performance measures. We also compared the application results of
the methods to a real dataset from the Korea adverse event reporting system (KAERS).

Life 2020, 10, 138

3 of 21

2. Signal Detection Method
Several different data mining methods have been developed to detect unusually high
disproportionate reporting rates from the large drug safety databases. In this paper, we considered
ROR, PRR, IC, LRT, GPS, BCPNN, new IC, sB, and TreeScan, which have been relatively widely used.
We mainly referred to Huang et al. [10] for a review of the methods apart from TreeScan.
From a large drug safety database, the number of AEs by drugs can be presented in matrix form
with I rows of AEs and J columns of drugs. For a particular AE (ith AE) at a particular drug (jth drug),
the data can be summarized in a 2 Ã— 2 table, as shown in Table 1.
Table 1. Adverse events count for the ith adverse event and the jth drug.
AE

jth Drug

All Other Drugs

Total

ith adverse event
All other adverse events

ni j
n. j âˆ’ ni j

ni. âˆ’ ni j
n.. âˆ’ ni. âˆ’ n. j + ni j

ni.
n.. âˆ’ ni.

Total

n. j

n.. âˆ’ n. j

n..

2.1. Frequentist Methods
2.1.1. Reporting Odds Ratio (ROR)
The ROR is the odds ratio that a particular AE is reported in patients who take a specific drug
compared to patients who take other drugs [2]. The ROR for the ith AE and the jth drug (RORij ) is
estimated as




nij / ni. âˆ’ nij
nij n.. âˆ’ ni. âˆ’ n.j + nij
 
 = 


ROÌ‚Rij = 
n. j âˆ’ nij / n.. âˆ’ ni. âˆ’ n.j + nij
ni. âˆ’ nij n.j âˆ’ nij

 

and if either ni. âˆ’ nij or n.j âˆ’ nij is equal to 0, then ROÌ‚Rij is not defined. The log-transformed ROÌ‚Rij
can be approximated to a normal distribution as follows:
 


 .

log ROÌ‚Rij âˆ¼ N log RORij , Ïƒ2ROR ,
ij

ÏƒÌ‚2ROR â‰ˆ
ij

1
1
1
1
+
+
.
+
nij
ni. âˆ’ nij
n.j âˆ’ nij
n.. âˆ’ ni. âˆ’ n.j + nij

We can obtain an approximate 100(1 âˆ’ Î±)% confidence interval (CI) for RORij as:
 

q

CIRORij ,100(1âˆ’Î±)% = exp log ROÌ‚Rij Â± z1âˆ’Î±/2 ÏƒÌ‚2ROR ,
ij

where z1âˆ’Î±/2 = Î¦(1 âˆ’ Î±/2) and Î¦ is the standard normal distributionâ€™s cumulative
distribution function.
The null and the alternative hypotheses to test whether the ith AE for the jth drug is a signal or
not are expressed as:
H0 : RORij = 1 vs. Ha : RORij > 1.
As Evans et al. [3] suggested, the lower bound of CIRORij ,100(1âˆ’Î±)% > 2, so we reject the null
hypothesis and conclude that the ith AE can be interpreted as a signal of the disproportionate rate
(SDR) for the jth drug.

Life 2020, 10, 138

4 of 21

2.1.2. Proportional Reporting Ratio (PRR)
The PRR is the ratio of the proportion of patients who reported a particular AE after taking a
specific drug to the proportion of patients who have taken other drugs that reported the same AE [3].
We estimate the PRR for the ith AE and the jth drug (PRRij ) as:
PRÌ‚Rij = 

nij /ni.
nij (n.. âˆ’ ni. )
.

= 
ni. n.j âˆ’ nij
n.j âˆ’ nij /(n.. âˆ’ ni. )





If ni. âˆ’ nij â‰ˆ ni. and n.. âˆ’ ni. âˆ’ n.j + nij â‰ˆ (n.. âˆ’ ni. ), then ROÌ‚Rij â‰ˆ PRÌ‚Rij . We use the normal


approximation for the distribution of log PRÌ‚Rij for inference as follows:
 




log PRÌ‚Rij âˆ¼ N log PRRij , Ïƒ2PRR ,
ij

ÏƒÌ‚2PRR â‰ˆ
ij

1
1
1
1
âˆ’
âˆ’
+
.
nij ni.
(n.. âˆ’ ni. )
n.j âˆ’ nij

Therefore, an approximate 100(1 âˆ’ Î±)% CI for PRRij is expressed as follows:

 
q

CIPRRij ,100(1âˆ’Î±)% = exp log PRÌ‚Rij Â± z1âˆ’Î±/2 ÏƒÌ‚2PRR .
ij

The null hypothesis of H0 : PRRij = 1 is rejected if the lower bound of CIPRRij ,100(1âˆ’Î±)% > 2,
as for PRR.
2.1.3. Information Component (IC)
The IC is based on the relative reporting rate RRij , which indicates how many particular events
were reported in excess for a specific drug over the expected number of reported counts under the null
nij
hypothesis that a drug and AE are independent. The relative reporting rate is estimated by E , where
ij

niÂ· nÂ·j

Eij = nÂ·Â· is the expected number of reports for the ith AE and the jth drug under the null hypothesis.
The IC for the ith AE and the jth drug is defined as follows:

ICij = log2 RRij =



log RRij
log 2

.

nij

Ë† ij = log
The ICij is estimated as IC
2 Eij for nij > 0, niÂ· > 0, and nÂ·j > 0. The estimated variance of


1
1
1
1
Ë† ij is given by ÏƒÌ‚2 ;
IC
+
+
. An approximate 100(1 âˆ’ Î±)% CI for ICij is expressed
2
n
n
n
Ë†
ICij

(log 2)

ij

iÂ·

as follows:
CI100(1âˆ’Î±)%

Â·j

ï£«
ï£¶
r

ï£¬ï£¬ 
ï£·ï£·
2
ï£¬
Ë†
= expï£¬ï£­log ICij Â± z1âˆ’ Î±2 ÏƒÌ‚ Ë† ï£·ï£·ï£¸.
ICij

If the lower bound of CI100(1âˆ’Î±)% > 1, the ith AE can be interpreted as a signal.
2.1.4. Likelihood Ratio Test-Based Method (LRT)
Huang et al. [4] proposed the likelihood ratio test statistic, which controls the type I error and
false discovery rates by using Monte Carlo hypothesis testing. The null and alternative hypotheses to
test whether the ith AE for a specific drug ( jâˆ— ) is a signal or not are expressed as follows:
H0 : pi = qi vs. Ha : pi > qi ,

Life 2020, 10, 138

5 of 21

where pi and qi are defined as the reporting rates of ith AE and other AEs for a specific drug, respectively.
The maximum likelihood ratio (MLR) is expressed as follows:
ï£«  n âˆ— nij  n âˆ— âˆ’n âˆ— n jâˆ— . âˆ’nijâˆ— ï£¶
.j
ij
ï£¬ï£¬ ij
ï£·ï£·
ï£¬ï£¬ ni.
ï£·ï£·
n.. âˆ’ni.
ï£¬
ï£·ï£· Ã— I (pÌ‚i > qÌ‚i ),
MLR = maxï£¬ï£¬
 n.jâˆ— n.jâˆ— âˆ’nijâˆ—
ï£·ï£¸
i ï£­
n..



where I() is the indicator function, pÌ‚i = nijâˆ— /ni. , and qÌ‚i = n.jâˆ— âˆ’ nijâˆ— /(n.. âˆ’ ni. ). As the distribution of
MLR under the null hypothesis is unknown, the Monte Carlo hypothesis testing is used to calculate
p-values. For details, see Section 2.3.
2.2. Bayesian Method
2.2.1. Gamma Poisson Shrinker (GPS)
DuMouchel [5] suggested the GPS method, which is an empirical Bayes signal detection method.
The GPS method uses the relative report rate, defined as follows:
Î»ij =

nij
Eij

, where Eij =

ni. Ã— n.j
n..

.

This indicates the actual frequency compared to the expected frequency. Eij is calculated under
the null hypothesis that there is no association between the drug-AE pairs. The null and alternative
hypotheses are expressed as follows:
H0 : Î»ij = 1 vs. Ha : Î»ij > 1.
The GPS method assumes that the model and prior distributions are as follows:
 
model : nij Î»ij âˆ¼iid Poisson Âµij ,
prior : Î»ij âˆ¼ w Ã— Gamma(Î±1 , Î²1 ) + (1 âˆ’ w) Ã— Gamma(Î±2 , Î²2 ),
where the observed report count nij follows the Poisson distribution with unknown mean Âµij = Eij Ã— Î»ij .
The relative report rate follows the mixture gamma distribution where Gamma(Î±, Î²) is a gamma
distribution with mean Î±/Î² and variance Î±/Î²2 and 0 < w < 1 is the prior probability that Î»ij came
from the first gamma distribution of mixture. The hyperparameters (Î±1 , Î²1 , Î±2 , Î²2 , w) are estimated
by the empirical Bayes method, which is also known as the maximum marginal likelihood.
As gamma distribution is a conjugate prior for Poisson distribution, the posterior distribution of
Î»ij can be obtained in a closed form as follows:


posterior : Î»ij nij âˆ¼ wâˆ—ij Ã— Gamma Î±1 + nij , Î²1 + Eij +





1 âˆ’ wâˆ—ij Ã— Gamma Î±2 + nij , Î²2 + Eij ,

where wâˆ—ij is the posterior probability that Î»ij came from the first gamma distribution of the mixture.
This is expressed as follows:
wâˆ—ij



w Ã— f nij Î±1 , Î²1 , Eij


,

=
w Ã— f nij Î±1 , Î²1 , Eij + (1 âˆ’ w) Ã— f nij Î±2 , Î²2 , Eij

Life 2020, 10, 138

6 of 21



where f nij Î±, Î², Eij is the marginal distribution. This marginal distribution follows the negative
binomial distribution as follows:
!
Eij
nij |Î±, Î², Eij âˆ¼ NB Î±,
,
Eij + Î²
!
r+xâˆ’1 x
p (1 âˆ’ p)r .
x
The 5th percentile of the posterior distribution of Î»ij (EB05) is used for decision making. EB05 can
be obtained by solving the equation as follows:

where NB(x|r, p) =

EB05(Î»ij )

Z
0.05 =



f Î»ij nij dÎ»ij .

0

This integral can be solved easily using iterative techniques such as Newtonâ€™s method. If EB05(Î»ij )
is greater than 2, this drug-adverse effect pair is considered a signal of disproportionate rates (SDR).
2.2.2. Bayesian Confidence Propagation Neural Network (BCPNN)
Bate et al. [6] proposed the BCPNN method based on the IC measure. In the BCPNN method,
the IC measure was defined as follows:
!
Î¸ij
ICij = log2
.
Î¸i. Ã— Î¸.j
The observed reporting counts and marginal counts are assumed to follow a binomial distribution
with a beta distribution for priors as follows:




nij Î¸ij âˆ¼ Bin n.. , Î¸ij with Î¸ij âˆ¼ Beta Î±ij , Î²ij ,
ni. |Î¸i. âˆ¼ Bin(n.. , Î¸i. ) with Î¸i. âˆ¼ Beta(Î±i. , Î²i. ),




n.j Î¸.j âˆ¼ Bin n.. , Î¸.j with Î¸.j âˆ¼ Beta Î±.j , Î². j ,
where Î±ij = Î±i. = Î²i. = Î±.j = Î². j = 1 and Î²ij =

1
E(ni. |Î¸i. )E(n.j Î¸.j )

âˆ’ 1.

Using the delta method, the posterior mean and variance of ICij can be obtained as follows:

nij + 1 (n.. + 1)2

,
(n.. + Î³)(ni. + 1) n.j + 1




E ICij data = log2



Var ICij data =
where Î³ = Î²Ì‚ij + 1 =

1
log2

ï£¹
!2 ï£®ï£¯
n.. âˆ’ n.j + 1 ï£ºï£ºï£º
ï£¯ï£¯ n.. âˆ’ nij + Î³ âˆ’ 1
n
âˆ’
n
+
1
..
i.
ï£¯ï£¯ 
ï£ºï£º,


+
+
ï£º
ï£¯ï£°
nij + 1 (1 + n.. + Î³) (ni. + 1)(n.. + 3)
n.j + 1 (n.. + 3) ï£»

(n.. +2)2
.
(ni. +1)(n.j +1)

The lower limit of the 95% credible interval for ICij is calculated by:
q




ICÎ±/2 = E ICij data âˆ’ z1âˆ’Î±/2 Var ICij data ,
and if sBÎ±,ij is greater than 2, this drug-AE pair is a possible signal with a higher reporting rate.

Life 2020, 10, 138

7 of 21

2.2.3. New IC Method
The new IC is an improved method for posterior inference in IC analysis, including an accurate
estimate for the mode and significantly improved
credibility
interval estimates. This method also


iid
assumes the number of reports nij âˆ¼ Poisson Î»ij Eij , where Î»ij denotes the relative reporting rate.
The prior of parameters Î»ij is given by Î»ij âˆ¼iid Gamma(0.5, 0.5), and the posterior distribution of Î»ij is


given by Î»ij data âˆ¼iid Gamma nij + 0.5, Eij + 0.5 . Then, the New ICij is the posterior mean of log2 Î»ij ,
which is E(log2 Î»ij data) ; log2

nij +0.5
Eij +0.5

.

The 95% credible interval limits (Î»0.025 , Î»0.975 ) are obtained by:
Z

Î»Î±



Gamma y nij + 0.5, Eij + 0.5 dy = Î±

0

for Î± = 0.025 and Î± = 0.975. If the lower limit Î»0.025 > 0, the ith AE can be interpreted as a signal.
2.2.4. Simplified Bayesian
For small datasets, the GPS method is usually not recommended because of instability in the
estimation of the hyperparameters. Thus, Huang et al. [9] suggested the simplified Bayesian (sB)
method, which assumes a weaker assumption on prior distribution than the GPS method. The sB
method uses a single gamma distribution as a prior as follows:
prior : Î»ij âˆ¼ Gamma(Î±, Î±),
with mean 1 and variance 1/Î±. Huang et al. [9] proposed using three values (0.5, 0.01, and 0.0001) for
Î±. They also called the prior distribution with Î± = 0.5 a less noninformative prior. The other prior
distributions were called noninformative priors. The posterior distribution is also a single gamma
distribution as follows:


posterior : Î»ij nij âˆ¼ Gamma Î± + nij , Î± + Eij .
The lower bound of the 95% credible interval for Î»ij (sBÎ±, ij ) is used for detecting signals of SDR.
sBÎ±, ij is expressed as follows:


Î± + nij
E Î»ij nij =
Î± + Eij

sBÎ±, ij



Î± + nij
Var Î»ij nij = 
2
Î± + Eij
q




= E Î»ij nij âˆ’ 1.645 Var Î»ij nij .

If sBÎ±,ij is greater than 2, this drug-AE pair is a possible signal with a higher reporting rate. With
Î± = 0.5, the sB method is identical to the new IC method [10]. Hence, we only included the sB method
in the simulation.
2.3. Tree-Based Scan Statistic
In a medical dictionary, all AEs are categorized into a hierarchical tree structure. Kulldorff
et al. [13,14] proposed the tree-based scan statistic, which simultaneously searches for signals at any
level (or layer) of AEs in a hierarchical structure. We call the last cell of the tree a leaf and the rest
a node. That is, the higher level of leaves is the node. A higher-level node is defined as the parent
node; the lower level node is defined as the child node. ci is the observed number of AEs for each leaf
P
P
I and C = i ci = i nij is the total observed number of AEs reported in patients who have taken a
P
P
specific drug j and X = i xi = i ni. is the total number of AEs reported in patients who have taken
any drugs.

Life 2020, 10, 138

8 of 21

When the branches of a tree are cut, the sum of the observed and total number of AEs in the leaves
P
P
of each cut, G, cG = iâˆˆG ci and xG = iâˆˆG xi , respectively, are obtained. G includes both the child
nodes and parent nodes as a unit of AE. For each cut G, we can calculate the log likelihood ratio and
test statistic:
!
!
c
C âˆ’ cG
LR(G) = cG log G + (C âˆ’ cG ) log
.
xG
X âˆ’ xG
!!
cG
C âˆ’ cG
T = maxLR(G) Ã— I
>
,
xG
X âˆ’ xG
G
where I() is the indicator function. The cut G that maximizes LR(G) is the most likely cut of related
AEs. The null hypothesis implies that the group defined by cut G has the same ratio of observed to
expected AEs as the rest of the tree. In inference, Monte Carlo hypothesis testing is used, calculating
the most likely cut in each random dataset. Firstly, the likelihood of the most likely cut in a real dataset
is calculated. Secondly, 9999 random datasets are generated under the null hypothesis and the test
statistic for each random dataset calculated. Then, the p-value is calculated as R/(9999 + 1), where R is
the rank of the test statistic of real dataset compared with random datasets.
The LRT and TreeScan methods basically use the same test statistic. Because the TreeScan considers
the hierarchical structure in nature, the distribution of the test statistic is also obtained by comparing all
possible cuts in the hierarchical structure. Even if the two methods detected the same signal, p-values
could be different.
3. Simulation Study
3.1. Data Generation and Evaluation Measures
We generated datasets that reflect WHO-ARTâ€™s hierarchical structure, which can be expressed
as system-organ classes (SOC), preferred terms (PT), and included terms (IT) for AEs [16]. In the
simulation study, we included only SOC and PT levels. To reduce the computation time, we only
considered 500 drugs and 300 AEs, which were randomly selected from a total of 2161 PT levels.
We followed the approach in the study by Huang et al. [4] to generate our simulation data.
First, we generated marginal counts of AEs n1. , . . . , nI. (I = 300) and drugs n.1 , . . . , n.J (J = 500)
as follows:
 

(n1. , . . . , nI. )|n.. âˆ¼ Multinomial n.. , PIu1 , . . . , PIuI
i = 1 ui
i=1 ui !!


u
u1
n.j , . . . , n.J |n.. âˆ¼ Multinomial n.. , PJ
, . . . , PJ J
,
j=1

uj

j=1

uj

P
where u âˆ¼ Uni f orm(0, 1) with n.. = Ii=1 ni. .
Next, we generated the number of cases reported for a specified drug ( jâˆ— ), n1 jâˆ— , . . . , nI jâˆ— using





n1 jâˆ— , . . . , nI jâˆ— n.jâˆ— âˆ¼ Multinomial n.jâˆ— , prr ,



n
n
where prr = rr1 jâˆ— Ã— r0 Ã— n1... , . . . , rrI jâˆ— Ã— r0 Ã— nI... is a vector of probabilities with rr1 jâˆ— , . . . , rrI jâˆ— as the
relative reporting rates. When r0 is considered as the baseline risk, prr has the constraints that
P
n
n
0 â‰¤ rrijâˆ— Ã— r0 Ã— ni... â‰¤ 1, i = 1, . . . , I, and Ii=1 rrijâˆ— Ã— r0 Ã— ni... = 1. Note that the number of reported cases
was generated for a specific drug, and hence the true signals are signals for each drug. This means
that the relative reporting rate for the AE with a true signal is higher than those for all the other AEs
for one fixed drug. If an AE is a true signal, the relative reporting rate is greater than 1, while the
relative reporting rate is equal to 1 when the AE is a false signal [11]. The cells for the true signals
were randomly selected first depending on the assumed proportion of true signals. The relative
reporting rate for each of the selected cells as true signals was generated from Uni f orm(1.2, 10) and
Uni f orm(1.2, 4).

Life 2020, 10, 138

9 of 21

While the TreeScan method detected signals simultaneously for both SOC and PT levels, all the
other methods detected signals from SOC and PT levels separately. To evaluate the performances of
the methods considering the hierarchical data structure, we merged two separate results from each
level for all methods except the TreeScan method.
We generated 1000 datasets for each of nine different settings with three different total sample
sizes (300,000, 500,000, 1,000,000) and three different percentages of true signals (3%, 5%, 10%). We used
five different cutoffs, which are the criteria for signal detection for each method. Different criteria have
been used depending on the organization for different methods [17]. In practice, one may change the
criteria based on experience. We used the same criterion of the lower bound of the 95% CI for fair
comparison in our simulation.
To compare the performance, we calculated the type I error rate, sensitivity, positive predicted
value (PPV), and power for specific drugs. Under the null hypothesis, the type I error is estimated
as follows:
# of times detecting at least one false âˆ’ positive signal
Type I error =
.
total # of simulated datasets
The sensitivity, PPV, and power are estimated as:
S

Sensitivity =

1 X # of true âˆ’ positive signals in sth simulated dataset
S
# of true signals in the sth simulated dataset
s=1

S

1 X # of true âˆ’ positive signals in sth simulated dataset
PPV =
S
# of detected signals in the sth simulated dataset
s=1

Power =

# of times detecting at least one signal
,
total # of simulated datasets

where S is the total number of simulated datasets with at least one signal detected. We used R software
3.5.2 version (Vienna, Austria) for all simulations and data analyses.
3.2. Results
3.2.1. Comparison of Type I Error Rate
To compare the type I error rate of each method and cutoff, all relative reporting rates were set
to 1 for each total sample size (Table 2). The type I error rates of the ROR, PRR, and IC methods
were relatively high for the standard cutoff and for all total sample sizes, which means that spurious
detection could frequently occur even when there are no actual signals. The type I error rates of the
GPS and sB methods were close to 0 for the standard cutoff and all total sample sizes. The type I error
rates of the ROR, PRR, IC, GPS, BCPNN, and sB methods varied depending on how the cutoff was set.
On the other hand, the type I error rates of the LRT and TreeScan methods were close to the prespecified
significance level in most cases, although the LRT method had slightly higher type I error rates.
Table 2. Comparison of type I error rates at various cutoff points when rr = 1.
Total Sample Size
Method

Cutoff *

ROR

1
1.5
2
2.5
3

300,000

500,000

1,000,000

Type I Error
1.000
1.000
0.999
0.978
0.939

1.000
0.999
0.979
0.931
0.861

0.999
0.991
0.914
0.790
0.679

Life 2020, 10, 138

10 of 21

Table 2. Cont.
Total Sample Size

300,000

500,000

1,000,000

Method

Cutoff *

Type I Error

PRR

1
1.5
2
2.5
3

1.000
1.000
0.999
0.974
0.934

1.000
0.998
0.978
0.929
0.860

0.999
0.991
0.910
0.786
0.676

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.995
0.992
0.828
0.607
0.284

0.998
0.994
0.717
0.499
0.212

1.000
0.993
0.546
0.335
0.121

LRT

0.2
0.1
0.05
0.025
0.01

0.241
0.124
0.068
0.044
0.031

0.215
0.107
0.063
0.039
0.012

0.207
0.117
0.053
0.029
0.020

GPS

1
1.5
2
2.5
3

0.567
0.009
0.000
0.000
0.000

0.615
0.010
0.000
0.000
0.000

0.656
0.005
0.000
0.000
0.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.371
0.024
0.000
0.000
0.000

0.949
0.113
0.003
0.000
0.000

0.959
0.078
0.003
0.001
0.000

sB

1
1.5
2
2.5
3

0.741
0.088
0.009
0.000
0.000

0.842
0.090
0.005
0.000
0.000

0.917
0.079
0.004
0.000
0.000

TreeScan

0.2
0.1
0.05
0.025
0.01

0.194
0.103
0.052
0.025
0.008

0.240
0.124
0.050
0.029
0.010

0.219
0.097
0.047
0.029
0.009

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

3.2.2. Comparison of Sensitivity, PPV, and Power
Tables 3 and 4 present the results for sensitivity, PPV, and power of each method when the total
sample size is equal to 300,000. The other results are presented in Appendix A. For all simulation
settings and the standard cutoff for each method, the ROR, PRR, and IC methods had relatively higher
sensitivity and power than the other methods. However, the LRT, GPS, BCPNN, sB, and TreeScan
methods had relatively higher PPV than the other methods. This means that the ROR, PRR, and IC
methods may detect too many signals regardless of whether they are actually true, so these methods
could detect many false signals as well as true ones. On the contrary, the LRT, GPS, BCPNN, sB,
and TreeScan methods detected much fewer signals, but more true signals than false ones.

Life 2020, 10, 138

11 of 21

Table 3. Summary of performance for each method at various cutoff points when the total sample size
= 300,000 and rr âˆ¼ U (1.2, 10).
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

ROR

1
1.5
2
2.5
3

0.996
0.996
0.996
0.996
0.996

0.753
0.704
0.655
0.608
0.559

0.251
0.388
0.503
0.587
0.646

0.997
0.997
0.997
0.997
0.997

0.728
0.678
0.624
0.569
0.519

0.394
0.534
0.628
0.692
0.737

0.999
0.999
0.999
0.999
0.999

0.680
0.621
0.561
0.498
0.438

0.649
0.744
0.800
0.833
0.854

PRR

1
1.5
2
2.5
3

0.996
0.996
0.996
0.996
0.996

0.753
0.704
0.654
0.607
0.557

0.251
0.389
0.504
0.588
0.647

0.997
0.997
0.997
0.997
0.997

0.728
0.678
0.623
0.568
0.516

0.394
0.535
0.629
0.693
0.738

0.999
0.999
0.999
0.999
0.999

0.680
0.621
0.560
0.497
0.436

0.649
0.744
0.800
0.833
0.855

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.991
0.986
0.980
0.976
0.963

0.687
0.612
0.541
0.500
0.413

0.309
0.614
0.825
0.877
0.938

0.995
0.991
0.984
0.982
0.977

0.660
0.579
0.507
0.467
0.375

0.479
0.757
0.881
0.917
0.956

0.995
0.992
0.990
0.989
0.986

0.613
0.526
0.448
0.405
0.311

0.748
0.904
0.951
0.963
0.978

LRT

0.2
0.1
0.05
0.025
0.01

0.939
0.929
0.915
0.901
0.881

0.462
0.432
0.409
0.387
0.359

0.962
0.981
0.990
0.994
0.997

0.956
0.945
0.930
0.922
0.908

0.417
0.388
0.365
0.341
0.314

0.983
0.990
0.992
0.995
0.999

0.973
0.969
0.961
0.947
0.932

0.338
0.312
0.289
0.267
0.240

0.990
0.995
0.996
1.000
1.000

GPS

1
1.5
2
2.5
3

0.891
0.888
0.888
0.888
0.886

0.417
0.415
0.414
0.406
0.369

0.997
0.998
0.998
0.998
0.999

0.926
0.925
0.925
0.924
0.911

0.395
0.393
0.391
0.373
0.315

0.998
0.998
0.998
0.998
0.999

0.951
0.951
0.950
0.945
0.913

0.378
0.378
0.369
0.312
0.204

0.997
0.997
0.998
1.000
1.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.948
0.914
0.867
0.808
0.719

0.578
0.443
0.335
0.246
0.174

0.731
0.984
0.998
1.000
1.000

0.951
0.924
0.893
0.831
0.753

0.539
0.398
0.291
0.204
0.138

0.857
0.992
0.999
1.000
1.000

0.972
0.950
0.911
0.837
0.754

0.474
0.323
0.216
0.139
0.081

0.957
0.998
1.000
1.000
1.000

sB

1
1.5
2
2.5
3

0.934
0.921
0.900
0.864
0.807

0.488
0.414
0.347
0.288
0.241

0.866
0.992
1.000
1.000
1.000

0.942
0.932
0.908
0.875
0.826

0.448
0.363
0.292
0.231
0.180

0.939
0.996
1.000
1.000
1.000

0.939
0.919
0.894
0.856
0.797

0.387
0.293
0.217
0.156
0.110

0.988
0.999
1.000
1.000
1.000

TreeScan

0.2
0.1
0.05
0.025
0.01

0.942
0.930
0.917
0.904
0.887

0.477
0.457
0.437
0.422
0.400

0.964
0.983
0.990
0.994
0.997

0.954
0.949
0.942
0.935
0.914

0.444
0.417
0.393
0.373
0.352

0.981
0.991
0.997
0.999
0.999

0.975
0.968
0.955
0.948
0.924

0.369
0.343
0.322
0.301
0.280

0.992
0.996
0.998
1.000
1.000

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

When the relative reporting rates were low (Table 4), all the methods had lower performance
compared to when the relative reporting rates were high (Table 3). The GPS, BCPNN, and sB methods
had a significant decrease in power and sensitivity, especially the GPS method.
As the percentage of true signals increased for all settings of total sample size, the sensitivity
decreased but the PPV and power increased for all methods. As the total sample size increased for all
settings of the percentage of true signals, the sensitivity, PPV, and power increased for all methods.
However, depending on the cutoff of each method, the sensitivity, PPV, and power varied. No single
method was superior to the others overall for all settings.

Life 2020, 10, 138

12 of 21

Table 4. Summary of performance for each method at various cutoff points when the total sample size
= 300,000 and rr âˆ¼ U (1.2, 4).
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

ROR

1
1.5
2
2.5
3

0.987
0.984
0.971
0.934
0.864

0.518
0.419
0.323
0.243
0.177

0.164
0.250
0.316
0.348
0.353

0.997
0.997
0.996
0.984
0.943

0.510
0.408
0.313
0.231
0.163

0.262
0.364
0.437
0.468
0.467

0.995
0.995
0.995
0.994
0.984

0.464
0.362
0.268
0.190
0.133

0.437
0.531
0.581
0.597
0.591

PRR

1
1.5
2
2.5
3

0.987
0.984
0.971
0.933
0.861

0.518
0.419
0.322
0.241
0.175

0.164
0.250
0.317
0.349
0.354

0.997
0.997
0.996
0.984
0.940

0.510
0.408
0.312
0.229
0.162

0.262
0.364
0.437
0.469
0.467

0.995
0.995
0.995
0.994
0.983

0.464
0.361
0.267
0.189
0.132

0.437
0.532
0.582
0.597
0.591

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.944
0.901
0.835
0.782
0.569

0.472
0.334
0.222
0.175
0.087

0.182
0.378
0.582
0.662
0.744

0.984
0.969
0.942
0.905
0.716

0.469
0.331
0.217
0.165
0.077

0.290
0.527
0.696
0.759
0.820

0.984
0.976
0.965
0.946
0.828

0.413
0.284
0.179
0.129
0.056

0.486
0.702
0.811
0.850
0.882

LRT

0.2
0.1
0.05
0.025
0.01

0.673
0.602
0.554
0.509
0.444

0.149
0.122
0.104
0.088
0.071

0.867
0.911
0.939
0.966
0.977

0.785
0.725
0.670
0.609
0.534

0.136
0.111
0.091
0.077
0.060

0.917
0.948
0.975
0.984
0.987

0.859
0.815
0.748
0.679
0.612

0.111
0.089
0.071
0.057
0.044

0.955
0.981
0.988
0.992
0.999

GPS

1
1.5
2
2.5
3

0.430
0.051
0.028
0.015
0.003

0.079
0.008
0.005
0.002
0.000

0.983
1.000
1.000
1.000
1.000

0.611
0.250
0.165
0.065
0.008

0.095
0.026
0.017
0.005
0.001

0.989
0.996
1.000
1.000
1.000

0.704
0.561
0.465
0.057
0.003

0.090
0.047
0.034
0.002
0.000

0.992
0.999
0.999
1.000
1.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.864
0.640
0.339
0.113
0.022

0.306
0.135
0.048
0.013
0.003

0.477
0.915
0.984
1.000
1.000

0.914
0.745
0.426
0.140
0.026

0.292
0.121
0.040
0.010
0.002

0.624
0.937
0.996
1.000
1.000

0.943
0.824
0.507
0.166
0.025

0.259
0.098
0.028
0.006
0.001

0.802
0.976
1.000
1.000
1.000

sB

1
1.5
2
2.5
3

0.669
0.472
0.247
0.084
0.016

0.171
0.080
0.031
0.009
0.002

0.860
0.991
0.996
1.000
1.000

0.743
0.569
0.294
0.094
0.021

0.161
0.072
0.024
0.006
0.001

0.927
0.995
1.000
1.000
1.000

0.778
0.628
0.345
0.098
0.018

0.133
0.052
0.015
0.003
0.001

0.969
0.997
1.000
1.000
1.000

TreeScan

0.2
0.1
0.05
0.025
0.01

0.671
0.619
0.573
0.520
0.452

0.148
0.125
0.107
0.092
0.074

0.866
0.930
0.961
0.970
0.985

0.772
0.726
0.671
0.614
0.550

0.137
0.114
0.096
0.082
0.065

0.919
0.965
0.982
0.990
0.993

0.843
0.792
0.729
0.685
0.609

0.110
0.088
0.073
0.061
0.048

0.945
0.964
0.983
0.991
0.995

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

4. Example
4.1. Korea Adverse Event Reporting System (KAERS)
The KAERS is a spontaneous reporting system that receives and manages adverse drug events
reported by patients, manufacturers, or medicine experts, provided by Korea Institute of Drug Safety and
Risk Management. It consists of drugs, AEs, basic demographic, and causality assessment information.
When reported, a drug and an AE should be reported together in a pair. These can be reported several
times depending on the dose and time. If the same drugs and AEs were reported in duplicate, depending
on dose or time, only the first report was counted. Therefore, drugs and AEs are paired only one time.
Causality was assessed at six levels: certain, probable, possible, unlikely, unclassified, and unassessable.
The assessment criteria are shown in Table 5. We used all drug-AE pairs except for ones with an unassessable
level. Not only the reported information on a possible causal relationship between an AE and a drug,

Life 2020, 10, 138

13 of 21

but also previously unknown or incompletely documented relationships can be a signal. The causality
assessment was performed by a reporter, such as a medical institution, expert, manufacturer, pharmacy, or
public health center.
Table 5. Causality assessment criteria.
Criterion

Level

The context of administration and use of medicines is reasonable.
It is not described as another medication, chemical, or accompanying illness.
In case of administration interruption, there is a clinically reasonable response.
In case of readministration, there is a pharmacologically conclusive response.
It could be described as another medication, chemical, or accompanying illness.
It is a temporary condition, not related to the administration and use of medicines.
It requires more information to assess or it is under examination.
It is not assessable and cannot be supplemented.

Certain, Probable, Possible
Certain, Probable
Certain, Probable
Certain
Possible, Unlikely
Unlikely
Unclassified
Unassessable

In KAERS, AEs were organized under the WHO-ARTâ€™s hierarchical structure [16]. This consists
of four hierarchical levels: system-organ class (SOC), high-level terms (HLT), preferred terms (PT),
and included terms (IT). SOC is the highest level. IT represents various expressions about the same AE
in the PT level. HLT is a set of PTs related to each other or having some similar symptoms. HLT may or
may not exist and therefore are excluded from the analysis. A small subset of the hierarchical structure
is listed in Table 6. However, in the KAERS database, more than half of the reports were reported up
to the PT level. Thus, we used the PT level as the lowest level of AEs. In the following illustration,
we used the SOC and PT levels in the WHO-ARTâ€™s hierarchical structure.
Table 6. Subset of WHO-ARTâ€™s hierarchical structure of adverse events.
Code

Level

Adverse Event

100
100.0001.001
100.0001.003
100.0001.004
100.0001.005
100.0001.006
100.0001.007
100.0001.008
100.0002.001
100.0002.003
100.0002.004
100.0002.005
100.0002.006
100.0002.007
100.0002.008
100.0002.009
100.0002.010
100.0002.011
100.0002.012
100.0002.013
100.0002.014
100.0002.015

SOC
PT
IT
IT
IT
IT
IT
IT
PT
IT
IT
IT
IT
IT
IT
IT
IT
IT
IT
IT
IT
IT

Skin and appendages disorders
ACNE
ACNEIFORM DERMATITIS
RASH ACNEIFORM
ACNE CYSTIC
ACNE PUSTULAR
ACNE AGGRAVATED
ACNE CONGLOBATA
ALOPECIA
HAIR THINNING
ALOPECIA AREATA
ATRICHIA
BALDNESS
HAIR LOSS
ATRICHOSIS
LOSS OF EYELASHES
ALOPECIA TOTALIS
ALOPECIA SCARRING
ALOPECIA UNIVERSALIS
DEFLUVIUM
LOSS OF EYEBROWS
AGGRAVATED HAIR LOSS

4.2. Data
We used drug-adverse effects pair data from KAERS between 2012 and 2016. Between 2012
and 2016, there were approximately 3.1 million drug-AE pairs with 1615 kinds of PT-level AEs and
1950 kinds of drugs. Restricting the causality assessment information to certain, probable, possible,
unlikely, or unclassified levels, approximately 2.5 million drug-AE pairs with 1484 kinds of PT level
AEs and 1716 kinds of drugs were left. These data contained 32 SOC levels, 1484 PT levels, and 3557 IT
levels. Analyses were done with these drug-AE pairs.

Life 2020, 10, 138

14 of 21

4.3. Analysis
We selected two diabetes drugs, voglibose and acarbose, to compare specific results. Both are
hypoglycemic agents that are used for type 2 diabetes, along with diet and exercise. These two drugs
were selected because of their substantial exposure and comparable characteristics. Voglibose has a
simple structure relative to acarbose. Moreover, it is known to be more economical and safer because
its absolute administration dose is 1000 times lower than that of acarbose. However, some severe
AEs tend to be more reported in voglibose [17,18]. Therefore, we found specific AEs in acarbose and
voglibose using KAERS data by the signal detection methods previously described.
First, we compared the number of signals detected by each method from all drug-adverse effect
pairs with 1484 kinds of PT level AEs and 1716 kinds of drugs. Second, the specific signals detected by
each method were compared for the two diabetes drugs mentioned above. The detection criteria for
each method are shown in Table 7 and the TreeScan method was performed with a simple cut.
Table 7. Signal detection criterion for each method.
Method

Detection Criterion

ROR, PRR
IC, BCPNN
GPS
BCPNN
sB
LRT, TreeScan

95% CI lower bound > 2
95% CI lower bound > log2(2)
EB05 > 2
95% CI lower bound > log2(2)
95% CI lower bound > 2
p-value < 0.05

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic.

4.4. Results
Table 8 provides the overall signal detection results of all methods. We used the signal detection
criteria presented in Table 7. We summarized the number of detected signals separately for PT and SOC
levels. The GPS, BCPNN, and sB methods detected relatively fewer signals than the other methods.
The ROR and PRR detected the most signals.
The results of applying all methods to two drugs, voglibose and acarbose, are summarized in
Table 9. We report only the AEs that were detected by more than two of the signal detection methods.
Voglibose had a higher reported count of all AEs than acarbose. The number of AEs detected by
at least one method was higher for voglibose (36 AEs) than for acarbose (31 AEs). For both drugs,
the common AEs detected were diarrhea, flatulence, and hypoglycemia at the PT level, and metabolic
and nutritional disorders at the SOC level. There was only one common AE detected by all methods
in acarbose and voglibose: flatulence at the PT level. Both drugs signaled strongly for flatulence,
which is an AE commonly observed in patients with type 2 diabetes [19,20]. In addition, the common
AEs detected by all methods were dyspepsia and hypoglycemia at the PT level, and metabolic and
nutritional disorders at the SOC level in voglibose.
Table 8. Overall detection: the number of signals detected by each method in the 2012â€“2016 Korea
adverse event reporting system (KAERS) database contained 1615 kinds of adverse events and 1716
kinds of drugs.
Method (# of Pairs)

ROR & PRR

IC

LRT

GPS

BCPNN

sB

TreeScan

PT levels (2,546,544)
SOC levels (54,912)
Total (2,601,456)

43,960
4142
48,102

25,714
2147
27,861

8324
2238
10,562

6147
1342
7489

5290
1256
6546

4397
1163
5560

9175
1380
10,555

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic.

Life 2020, 10, 138

15 of 21

Table 9. Detected signals by each method for voglibose and acarbose.

Voglibose

Acarbose

Adverse Event

Obs

Exp

ROR

PRR

IC

LRT

GPS

BCPNN

sB

TreeScan

500_165

Anorexia

8

2.62

2.42 *

2.42 *

0.59

0.940

1.12

0.35

1.37

0.504

600
600_204
600_205
600_268
600_279
600_285

Gastrointestinal system disorders
Constipation
Diarrhea
Abdominal pain
Dyspepsia
Flatulence

115
11
12
10
35
15

73.73
3.96
6.43
3.63
7.22
0.39

1.83
2.26 *
1.33
2.20 *
5.16 *
40.28 *

1.83
2.26 *
1.33
2.20 *
5.15 *
40.00 *

0.32
0.60
0.06
0.55
1.77 *
4.49 *

0.001 *
0.782
1.000
0.910
0.001 *
0.001 *

1.28
1.24
0.92
1.17
3.11 *
20.89 *

0.31
0.43
0.00
0.37
1.62 *
2.79 *

1.46
1.47
1.23
1.43
3.64 *
10.76 *

0.001 *
0.336
0.980
0.447
0.001 *
0.001 *

800
800_389
800_392
800_407

Metabolic and nutritional disorders
Hypoglycemia
Hyponatremia
Weight decrease

37
24
2
2

5.07
0.55
0.18
0.21

8.11 *
48.25 *
9.67 *
8.19 *

8.10 *
47.86 *
9.65 *
8.18 *

2.37 *
4.84 *
1.44 *
1.24 *

0.001 *
0.001 *
0.996
0.998

4.67 *
27.47 *
0.49
0.47

2.15 *
3.41 *
âˆ’0.30
âˆ’0.34

6.11 *
17.12 *
0.03
0.04

0.001 *
0.001 *
0.772
0.860

1100
1100_515
1100_523

Respiratory system disorders
Epistaxis
Pharyngitis

16
2
4

9.46
0.21
0.85

1.23
8.18 *
3.79 *

1.23
8.17 *
3.79 *

0.03
1.24 *
0.81

1.000
0.998
0.992

0.94
0.47
0.85

âˆ’0.02
âˆ’0.34
0.15

1.21
0.04
0.80

0.981
0.861
0.745

1810_401

Edema peripheral

3

0.71

3.15 *

3.15 *

0.44

1.000

0.60

âˆ’0.20

0.43

0.973

500_172

Depression

2

0.08

25.07 *

25.02 *

2.68 *

0.638

0.66

âˆ’0.18

0.04

0.209

600_205
600_285
600_336

Diarrhea
Flatulence
Tooth disorder

7
12
2

3.01
0.18
0.01

1.65
72.43 *
180.65 *

1.64
72.02 *
177.84 *

0.11
5.16 *
5.43 *

1.000
0.001 *
0.010 *

0.84
31.93 *
1.88

âˆ’0.05
2.62 *
âˆ’0.10

0.90
10.06 *
0.02

0.924
0.001 *
0.008 *

800
800_383
800_389

Metabolic and nutritional disorders
Hyperkalemia
Hypoglycemia

6
2
3

2.38
0.11
0.26

1.79
17.08 *
10.77 *

1.79
17.06 *
10.76 *

0.15
2.16 *
1.88 *

1.000
0.846
0.632

0.81
0.58
0.91

âˆ’0.06
âˆ’0.22
0.23

0.89
0.03
0.64

0.920
0.390
0.202

1210
1210_544

Red blood cell disorders
Anemia

4
4

0.62
0.51

5.70 *
7.13 *

5.70 *
7.13 *

1.26 *
1.54 *

0.798
0.556

1.00
1.10

0.33
0.43

0.98
1.05

0.326
0.176

1300
1300_619

Urinary system disorders
Renal function abnormal

6
2

2.16
0.11

2.06 *
16.52 *

2.06 *
16.50 *

0.29
2.12 *

0.998
0.860

0.87
0.57

0.04
âˆ’0.23

0.91
0.03

0.819
0.396

1810_711

Abdomen enlarged

2

0.08

25.76 *

25.71 *

2.72 *

0.632

0.66

âˆ’0.18

0.02

0.197

Obs, Observed count; Exp, Expected count; ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio test; GPS, Gamma Poisson
Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified Bayes; TreeScan, Tree-based Scan Statistic; * signal.

Life 2020, 10, 138

16 of 21

5. Discussion
A number of disproportionality methods for data mining and the TreeScan method were compared
for signal detection during drug surveillance for AEs data grouped into hierarchical structures.
We included various frequentist methods such as ROR, PRR, IC, LRT, and TreeScan as well as Bayesian
methods such as GPS, BCPNN, and sB. The LRT, GPS, BCPNN, sB, and TreeScan methods detected
fewer signals than the ROR, PRR, and IC methods. The power and sensitivity of the GPS, sB, LRT,
and TreeScan methods tended to be lower than those of others, which implies that these methods are
more conservative. The higher power and sensitivity of the ROR, PRR, and IC methods seemed to be
due to the higher type I error rates. The three methods had lower PPV. The TreeScan method controls
the type I error rate at the desired level, while other methods cannot control this or find appropriate
cutoffs for the desired type I error rate. However, no method was superior to the others in relation to
all performance measures.
We observed similar patterns in the analysis results of the KAERS data. The GPS and sB methods
detected much fewer signals than the others overall. For the two specific drugs, some common AEs
were detected by all methods. The ROR, PRR, and IC methods detected additional signals that were
not detected by the GPS, sB, LRT, or TreeScan methods. The ROR and PRR methods detected rather
too many signals, even if the number reported was small. Thus, the restriction of three or more cases
for the reported count to be a signal for the ROR and PRR methods, which is usually imposed in
practice [3], might be sensible.
In terms of computation time, the GPS, LRT, and TreeScan methods are more intensive relative
to the other methods. Other methods have a closed form for the confidence interval of each statistic,
so only the cell count (nij ) and marginal count (ni. or n.j ) of the matrix are required to calculate the
confidence interval. On the other hand, the GPS method requires all cell counts in the matrix to estimate
the parameters of prior distribution. For the LRT and TreeScan method, a Monte Carlo simulation is
required to obtain p-values.
The methods considered in this paper are approaches that can be applied to an existing database.
In some cases, one may want to continuously or sequentially monitor to detect a signal as early
as possible. The sequential probability ratio test (SPRT) [21,22] can be used. The method has also
been applied to a spontaneous adverse event reporting system [23,24]. However, the result of the
SPRT method is highly dependent on the relative risk used to specify the alternative hypothesis [25].
Although we did not include the SPRT in this study for these reasons, it would be interesting to
compare the method in appropriate situations in future research.
The drug safety databases such as KAERS are constructed by a spontaneous reporting system and
very few AEs that occur were reported, so it has a large number of zero-count cells. In this situation,
a zero-inflated Poisson model could be considered. Hu et al. [11] proposed ZIP-sB and ZIP-DP (Dirichlet
process). Huang et al. [26] proposed a zero-inflated Poisson (ZIP) model based on the likelihood ratio
test. According to these research findings, ZIP models detected fewer signals in data containing a large
number of zero-counts. This means that they are more conservative by considering zero-counts. In a
further study, we will evaluate the performance of ZIP models and apply them to real data to compare.
Huang et al. proposed extending the likelihood ratio test-based (LRT) methods [9] that can
detect signals for including a single AE or several AEs within one AE group. The extended LRT
method could be used for hierarchical structures of AEs for a fixed drug. The threshold for a signal for
multiple-layer analysis should be higher than that for single-layer analysis. It will be very interesting to
see the simulation results by comparing the Extended LRT vs. TreeScan with multiple layers (PT, SOC,
or others). This is a future research topic.
Currently, some drug companies have different AE detection criteria. For example, AstraZeneca
detects an AE when the EB05 is greater than 1.8, whereas GlaxoSmithKline detects AE when it is
greater than 2 [12]. In our study, it was confirmed that the performance of each method could vary
depending on the cutoff, which is the criteria for signal detection in simulation. Therefore, how to set
the cutoff for signal detection is very important and worth noting.

Life 2020, 10, 138

17 of 21

6. Conclusions
In summary, the LRT, GPS, BCPNN, sB, and TreeScan methods are more conservative than the
ROR, PRR, and IC methods. Only the TreeScan method controls the type I error rate at the desired
level. No method is superior to the others in relation to all performance measures. It is recommended
that those conducting drug-AE surveillance use not just one method, but make a decision based on
several methods.
Author Contributions: Conceptualization, I.J.; Data curation, G.P., H.J., and S.-J.H.; Formal analysis, G.P., H.J.,
and S.-J.H.; Funding acquisition, I.J.; Investigation, G.P., H.J., S.-J.H., and I.J.; Methodology, G.P., H.J., S.-J.H., and
I.J.; Project administration, I.J.; Software, S.-J.H.; Supervision, I.J.; Validation, G.P., and H.J.; Writingâ€”original
draft, G.P., H.J., and S.-J.H.; Writingâ€”review and editing, I.J. All authors have read and agreed to the published
version of the manuscript.
Funding: This research was supported by Basic Science Research Program through the National Research
Foundation of Korea (NRF), funded by the Ministry of Education (2019R1F1A1057182).
Acknowledgments: We are very grateful to the reviewers for their insightful comments.
Conflicts of Interest: The authors declare no conflict of interest.

Appendix A
Table A1. Summary of performance for each method at various cutoff points when the total sample
size = 500,000 and rr âˆ¼ U (1.2, 10).
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

ROR

1
1.5
2
2.5
3

0.996
0.996
0.995
0.994
0.994

0.799
0.747
0.696
0.641
0.590

0.303
0.493
0.621
0.694
0.740

0.995
0.995
0.995
0.995
0.995

0.764
0.709
0.651
0.595
0.539

0.462
0.631
0.726
0.780
0.813

0.998
0.998
0.998
0.998
0.998

0.728
0.663
0.596
0.532
0.465

0.729
0.821
0.865
0.888
0.904

PRR

1
1.5
2
2.5
3

0.996
0.996
0.995
0.994
0.994

0.799
0.747
0.695
0.639
0.588

0.303
0.495
0.622
0.695
0.741

0.995
0.995
0.995
0.995
0.995

0.764
0.708
0.650
0.593
0.537

0.462
0.631
0.727
0.781
0.813

0.998
0.998
0.998
0.998
0.998

0.728
0.663
0.596
0.530
0.462

0.729
0.821
0.865
0.889
0.904

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.993
0.992
0.990
0.983
0.975

0.758
0.689
0.619
0.583
0.494

0.285
0.663
0.866
0.910
0.952

0.994
0.992
0.992
0.988
0.987

0.735
0.658
0.586
0.540
0.446

0.468
0.810
0.922
0.944
0.973

0.992
0.991
0.987
0.987
0.984

0.682
0.593
0.512
0.466
0.366

0.760
0.927
0.967
0.978
0.985

LRT

0.2
0.1
0.05
0.025
0.01

0.958
0.955
0.946
0.938
0.935

0.558
0.535
0.515
0.495
0.471

0.962
0.979
0.988
0.995
0.999

0.974
0.967
0.961
0.955
0.944

0.527
0.502
0.477
0.456
0.433

0.989
0.994
0.997
0.999
0.999

0.974
0.966
0.959
0.959
0.949

0.440
0.414
0.392
0.370
0.344

0.994
0.997
1.000
1.000
1.000

GPS

1
1.5
2
2.5
3

0.926
0.925
0.925
0.922
0.918

0.511
0.509
0.506
0.487
0.430

0.998
0.998
0.999
0.999
0.999

0.934
0.934
0.934
0.932
0.926

0.493
0.491
0.482
0.439
0.353

0.999
0.999
0.999
0.999
1.000

0.968
0.968
0.967
0.965
0.947

0.478
0.476
0.447
0.355
0.242

0.999
0.999
0.999
0.999
1.000

sB

1
1.5
2
2.5
3

0.940
0.929
0.910
0.880
0.841

0.593
0.505
0.426
0.362
0.310

0.845
0.990
0.998
1.000
1.000

0.962
0.948
0.938
0.920
0.889

0.552
0.462
0.373
0.298
0.234

0.937
0.997
1.000
1.000
1.000

0.961
0.954
0.948
0.934
0.902

0.491
0.388
0.301
0.226
0.162

0.987
0.999
1.000
1.000
1.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.964
0.947
0.930
0.893
0.837

0.670
0.542
0.435
0.342
0.268

0.737
0.982
1.000
1.000
1.000

0.972
0.960
0.936
0.907
0.875

0.646
0.509
0.396
0.299
0.223

0.870
0.996
1.000
1.000
1.000

0.972
0.958
0.937
0.914
0.865

0.568
0.422
0.305
0.215
0.142

0.964
0.999
1.000
1.000
1.000

Life 2020, 10, 138

18 of 21

Table A1. Cont.
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

TreeScan

0.2
0.1
0.05
0.025
0.01

0.956
0.951
0.942
0.932
0.921

0.569
0.550
0.534
0.519
0.495

0.970
0.985
0.990
0.996
0.999

0.960
0.957
0.951
0.940
0.929

0.525
0.504
0.485
0.471
0.450

0.981
0.992
0.995
0.998
1.000

0.981
0.976
0.968
0.961
0.957

0.464
0.440
0.419
0.400
0.376

0.996
0.997
0.999
1.000
1.000

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

Table A2. Summary of performance for each method at various cutoff points when the total sample
size = 1,000,000 and rr âˆ¼ U (1.2, 10).
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

ROR

1
1.5
2
2.5
3

0.997
0.997
0.997
0.997
0.997

0.853
0.800
0.745
0.691
0.640

0.391
0.649
0.763
0.818
0.852

0.996
0.996
0.996
0.996
0.996

0.829
0.772
0.710
0.645
0.587

0.569
0.755
0.834
0.871
0.892

1.000
1.000
1.000
1.000
1.000

0.779
0.711
0.645
0.575
0.502

0.810
0.886
0.916
0.932
0.941

PRR

1
1.5
2
2.5
3

0.997
0.997
0.997
0.997
0.997

0.853
0.800
0.745
0.691
0.638

0.391
0.650
0.763
0.819
0.852

0.996
0.996
0.996
0.996
0.996

0.829
0.772
0.709
0.645
0.585

0.569
0.755
0.835
0.871
0.893

1.000
1.000
1.000
1.000
1.000

0.779
0.711
0.644
0.574
0.501

0.810
0.886
0.916
0.932
0.941

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.994
0.992
0.989
0.986
0.983

0.837
0.766
0.694
0.651
0.556

0.263
0.748
0.912
0.943
0.971

0.992
0.990
0.988
0.988
0.987

0.817
0.739
0.663
0.622
0.525

0.451
0.859
0.954
0.967
0.983

1.000
1.000
1.000
0.998
0.994

0.777
0.686
0.600
0.550
0.438

0.794
0.960
0.983
0.987
0.991

LRT

0.2
0.1
0.05
0.025
0.01

0.969
0.966
0.959
0.953
0.949

0.664
0.645
0.625
0.607
0.584

0.982
0.992
0.996
0.998
1.000

0.982
0.978
0.971
0.971
0.967

0.642
0.623
0.605
0.589
0.567

0.992
0.996
1.000
1.000
1.000

0.988
0.986
0.982
0.977
0.972

0.571
0.550
0.532
0.513
0.492

0.997
0.999
0.999
0.999
1.000

GPS

1
1.5
2
2.5
3

0.954
0.954
0.953
0.953
0.952

0.641
0.639
0.625
0.577
0.501

0.998
0.998
0.998
0.998
0.998

0.967
0.967
0.967
0.965
0.964

0.621
0.619
0.587
0.522
0.428

0.999
0.999
0.999
1.000
1.000

0.980
0.979
0.978
0.974
0.963

0.590
0.583
0.524
0.422
0.314

0.999
0.999
1.000
1.000
1.000

sB

1
1.5
2
2.5
3

0.976
0.958
0.941
0.921
0.889

0.756
0.640
0.537
0.450
0.372

0.753
0.991
1.000
1.000
1.000

0.983
0.968
0.962
0.949
0.938

0.743
0.617
0.515
0.420
0.334

0.892
0.998
1.000
1.000
1.000

0.990
0.976
0.970
0.958
0.939

0.683
0.545
0.426
0.324
0.237

0.977
1.000
1.000
1.000
1.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.970
0.961
0.953
0.941
0.926

0.716
0.635
0.545
0.472
0.406

0.825
0.994
1.000
1.000
1.000

0.971
0.966
0.962
0.955
0.948

0.681
0.583
0.491
0.409
0.335

0.937
0.997
0.999
1.000
1.000

0.968
0.961
0.955
0.943
0.932

0.609
0.508
0.411
0.326
0.247

0.989
1.000
1.000
1.000
1.000

TreeScan

0.2
0.1
0.05
0.025
0.01

0.972
0.966
0.964
0.959
0.955

0.688
0.673
0.658
0.646
0.627

0.980
0.988
0.992
0.996
0.997

0.979
0.977
0.974
0.966
0.963

0.651
0.632
0.615
0.603
0.581

0.992
0.996
0.997
1.000
1.000

0.985
0.983
0.983
0.977
0.968

0.574
0.553
0.533
0.518
0.500

0.999
0.999
1.000
1.000
1.000

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

Life 2020, 10, 138

19 of 21

Table A3. Summary of performance for each method at various cutoff points when the total sample
size = 500,000 and rr âˆ¼ U (1.2, 4).
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

ROR

1
1.5
2
2.5
3

0.991
0.989
0.979
0.954
0.859

0.592
0.471
0.360
0.260
0.174

0.204
0.341
0.434
0.465
0.453

0.997
0.997
0.996
0.989
0.948

0.571
0.452
0.340
0.238
0.158

0.313
0.465
0.547
0.576
0.564

0.996
0.996
0.996
0.996
0.990

0.522
0.403
0.294
0.198
0.128

0.510
0.637
0.686
0.693
0.673

PRR

1
1.5
2
2.5
3

0.991
0.989
0.978
0.954
0.852

0.592
0.470
0.359
0.258
0.172

0.204
0.342
0.434
0.466
0.450

0.997
0.997
0.996
0.989
0.944

0.571
0.451
0.339
0.237
0.156

0.313
0.465
0.548
0.576
0.563

0.996
0.996
0.996
0.996
0.989

0.522
0.403
0.292
0.197
0.126

0.510
0.638
0.686
0.694
0.673

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.968
0.948
0.914
0.880
0.647

0.578
0.430
0.296
0.229
0.106

0.177
0.457
0.698
0.777
0.850

0.979
0.966
0.944
0.922
0.769

0.556
0.402
0.274
0.210
0.093

0.281
0.592
0.777
0.829
0.881

0.987
0.981
0.965
0.956
0.857

0.511
0.358
0.231
0.171
0.068

0.493
0.771
0.866
0.897
0.909

LRT

0.2
0.1
0.05
0.025
0.01

0.810
0.763
0.721
0.684
0.639

0.230
0.202
0.180
0.161
0.139

0.910
0.951
0.973
0.987
0.995

0.860
0.827
0.794
0.769
0.722

0.210
0.183
0.159
0.140
0.119

0.940
0.966
0.982
0.991
0.992

0.918
0.889
0.860
0.833
0.784

0.179
0.154
0.134
0.117
0.097

0.968
0.982
0.991
0.996
0.999

GPS

1
1.5
2
2.5
3

0.650
0.164
0.062
0.019
0.006

0.163
0.025
0.009
0.002
0.001

0.979
0.994
1.000
1.000
1.000

0.745
0.360
0.150
0.056
0.005

0.179
0.047
0.018
0.004
0.000

0.984
1.000
1.000
1.000
1.000

0.792
0.529
0.170
0.016
0.001

0.185
0.047
0.011
0.001
0.000

0.990
1.000
1.000
1.000
1.000

sB

1
1.5
2
2.5
3

0.917
0.790
0.533
0.210
0.051

0.421
0.210
0.090
0.025
0.005

0.511
0.947
0.999
1.000
1.000

0.942
0.841
0.607
0.276
0.056

0.386
0.186
0.071
0.021
0.003

0.652
0.968
0.997
1.000
1.000

0.969
0.894
0.709
0.300
0.048

0.351
0.155
0.055
0.012
0.002

0.833
0.979
0.999
1.000
1.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.807
0.655
0.384
0.150
0.044

0.279
0.140
0.057
0.017
0.004

0.860
0.991
0.999
1.000
1.000

0.841
0.716
0.502
0.208
0.049

0.260
0.127
0.051
0.015
0.003

0.924
0.995
0.999
1.000
1.000

0.851
0.747
0.548
0.201
0.029

0.222
0.100
0.033
0.007
0.001

0.980
0.997
1.000
1.000
1.000

TreeScan

0.2
0.1
0.05
0.025
0.01

0.815
0.776
0.736
0.691
0.632

0.230
0.202
0.177
0.157
0.133

0.918
0.948
0.971
0.983
0.992

0.855
0.833
0.792
0.749
0.693

0.214
0.187
0.162
0.143
0.120

0.945
0.966
0.978
0.988
0.991

0.891
0.852
0.820
0.784
0.748

0.181
0.156
0.135
0.118
0.098

0.965
0.982
0.989
0.990
0.994

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

Table A4. Summary of performance for each method at various cutoff points when the total sample
size = 1,000,000 and rr âˆ¼ U (1.2, 4).
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

ROR

1
1.5
2
2.5
3

0.993
0.993
0.985
0.960
0.860

0.677
0.541
0.406
0.279
0.175

0.266
0.512
0.607
0.633
0.611

0.996
0.996
0.996
0.991
0.950

0.662
0.520
0.382
0.257
0.153

0.401
0.621
0.692
0.715
0.694

0.999
0.999
0.999
0.999
0.979

0.629
0.477
0.337
0.212
0.120

0.633
0.774
0.818
0.821
0.795

PRR

1
1.5
2
2.5
3

0.993
0.993
0.985
0.959
0.855

0.677
0.541
0.403
0.277
0.172

0.266
0.513
0.608
0.633
0.610

0.996
0.996
0.996
0.991
0.945

0.662
0.520
0.380
0.255
0.149

0.401
0.621
0.692
0.715
0.694

0.999
0.999
0.999
0.999
0.978

0.629
0.476
0.336
0.210
0.117

0.633
0.774
0.818
0.822
0.793

Life 2020, 10, 138

20 of 21

Table A4. Cont.
True Signal Ratio

0.03

0.05

0.1

Method

Cutoff *

Power

Sensitivity

PPV

Power

Sensitivity

PPV

Power

Sensitivity

PPV

IC

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.986
0.975
0.953
0.932
0.760

0.705
0.537
0.383
0.300
0.140

0.164
0.585
0.818
0.869
0.922

0.989
0.981
0.970
0.957
0.855

0.687
0.517
0.359
0.277
0.116

0.272
0.704
0.870
0.906
0.942

0.996
0.994
0.992
0.986
0.924

0.660
0.479
0.318
0.234
0.086

0.508
0.856
0.934
0.947
0.960

LRT

0.2
0.1
0.05
0.025
0.01

0.899
0.885
0.871
0.855
0.837

0.382
0.357
0.333
0.310
0.285

0.941
0.964
0.979
0.992
0.997

0.925
0.907
0.897
0.885
0.859

0.347
0.316
0.291
0.270
0.244

0.964
0.985
0.994
0.998
0.999

0.952
0.941
0.935
0.918
0.895

0.312
0.284
0.259
0.236
0.211

0.988
0.995
0.996
0.999
1.000

GPS

1
1.5
2
2.5
3

0.838
0.813
0.768
0.362
0.033

0.298
0.262
0.191
0.049
0.003

0.995
0.999
1.000
1.000
1.000

0.866
0.841
0.771
0.372
0.038

0.292
0.253
0.156
0.032
0.002

0.995
0.999
1.000
1.000
1.000

0.902
0.811
0.583
0.136
0.004

0.330
0.177
0.064
0.006
0.000

0.991
0.999
1.000
1.000
1.000

sB

1
1.5
2
2.5
3

0.961
0.892
0.764
0.449
0.124

0.562
0.338
0.179
0.063
0.013

0.561
0.967
1.000
1.000
1.000

0.963
0.917
0.797
0.509
0.132

0.525
0.300
0.138
0.046
0.009

0.707
0.983
1.000
0.998
1.000

0.967
0.944
0.855
0.544
0.121

0.491
0.261
0.106
0.027
0.004

0.872
0.996
0.999
1.000
1.000

BCPNN

log2 (1)
log2 (1.5)
log2 (2)
log2 (2.5)
log2 (3)

0.915
0.843
0.655
0.355
0.094

0.441
0.265
0.131
0.048
0.010

0.860
0.996
1.000
1.000
1.000

0.929
0.863
0.719
0.426
0.114

0.417
0.239
0.112
0.037
0.007

0.921
0.998
1.000
1.000
1.000

0.927
0.885
0.788
0.460
0.086

0.383
0.205
0.083
0.021
0.003

0.979
1.000
1.000
1.000
1.000

TreeScan

0.2
0.1
0.05
0.025
0.01

0.913
0.899
0.879
0.854
0.834

0.378
0.348
0.323
0.300
0.273

0.956
0.977
0.988
0.993
0.997

0.932
0.913
0.896
0.877
0.846

0.346
0.319
0.297
0.273
0.245

0.967
0.988
0.991
0.996
0.999

0.955
0.935
0.910
0.905
0.885

0.313
0.285
0.261
0.241
0.215

0.986
0.992
0.995
0.997
0.997

ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; IC, Information Component; LRT, Likelihood ratio
test; GPS, Gamma Poisson Shrinker; BCPNN, Bayesian Confidence Propagation Neural Network; sB simplified
Bayes; TreeScan, Tree-based Scan Statistic; * Cutoff values for the lower bound of the 95% CI for ROR, PRR, IC,
BCPNN, and sB, for EB05 for GPS, and for the p-value for LRT and TreeScan.

References
1.
2.
3.

4.
5.
6.

7.

8.

Korea Institution of Drug Safety & Risk Management. Guideline for KIDS-Korea Adverse Event Reporting System
Database; Korea Institution of Drug Safety & Risk Management: Seoul, Korea, 2017.
Rothman, K.J.; Lanes, S.; Sacks, S.T. The reporting odds ratio and its advantages over the proportional
reporting ratio. Pharmacoepidemiol. Drug Saf. 2004, 13, 519â€“523. [CrossRef] [PubMed]
Evans, S.J.; Waller, P.C.; Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from
spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 2001, 10, 483â€“486. [CrossRef]
[PubMed]
Huang, L.; Zalkikar, J.; Tiwari, R.C. A likelihood ratio test based method for signal detection with application
to FDAâ€™s drug safety data. J. Am. Stat. Assoc. 2011, 106, 1230â€“1241. [CrossRef]
Dumouchel, W. Bayesian Data mining in large frequency tables, with an application to the FDA apontaneous
reporting system. Am. Stat. 1999, 53, 177â€“190.
Bate, A.; Lindquist, M.; Edwards, I.R.; Olsson, S.; Orre, R.; Lansner, A.; De Freitas, R.M. A bayesian neural
network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 1998, 54, 315â€“321.
[CrossRef]
Noren, G.N.; Bate, A.; Orre, R.; Edwards, I.R. Extending the methods used to screen the WHO drug safety
database towards analysis of complex associations and improved accuracy for rare events. Stat. Med. 2006,
25, 3740â€“3757. [CrossRef]
NorÃ©n, G.N.; Edwards, I.R. Opportunities and challenges of adverse drug reaction surveillance in electronic
patient records. Pharmacovigil. Rev. 2010, 4, 17â€“20.

Life 2020, 10, 138

9.
10.
11.
12.

13.
14.

15.

16.

17.

18.
19.
20.
21.
22.
23.

24.
25.
26.

21 of 21

Huang, L.; Zalkikar, J.; Tiwari, R.C. Likelihood ratio test-based method for signal detection in drug classes
using FDAâ€™s AERS database. J. Biopharm. Stat. 2013, 23, 178â€“200. [CrossRef]
Huang, L.; Guo, T.; Zalkikar, J.N.; Tiwari, R.C. A review of statistical methods for safety surveillance.
Ther. Innov. Regul. Sci. 2014, 48, 98â€“108. [CrossRef]
Hu, N.; Huang, L.; Tiwari, R.C. Signal detection in FDA AERS database using Dirichlet process. Stat. Med.
2015, 34, 2725â€“2742. [CrossRef]
Candore, G.; Juhlin, K.; Manlik, K.; Thakrar, B.; Quarcoo, N.; Seabroke, S.; Wisniewski, A.; Slattery, J.
Comparison of statistical signal detection methods within and across spontaneous reporting databases.
Drug Saf. 2015, 38, 577â€“587. [CrossRef] [PubMed]
Kulldorff, M.; Fang, Z.; Walsh, S.J. A tree-based scan statistic for database disease surveillance. Biometrics
2003, 59, 323â€“331. [CrossRef] [PubMed]
Kulldorff, M.; Dashevsky, I.; Avery, T.R.; Chan, A.K.; Davis, R.L.; Graham, D.; Platt, R.; Andrade, S.E.;
Boudreau, D.; Gunter, M.; et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol. Drug
Saf. 2013, 22, 517â€“523. [CrossRef]
Brown, J.S.; Petronis, K.R.; Bate, A.; Zhang, F.; Dashevsky, I.; Kulldorff, M.; Avery, T.R.; Davis, R.L.; Chan, K.A.;
Andrade, S.E.; et al. Drug adverse event detection in health plan data using the gamma poisson shrinker and
comparison to the tree-based scan statistic. Pharmaceutics 2013, 5, 179â€“200. [CrossRef]
The Uppsala Monitoring Centre: The WHO Adverse Reaction Terminologyâ€”WHO-ART, Terminology for
Coding Clinical Information in Relation to Drug Therapy. 2015. Available online: https://www.who-umc.
org/vigibase/services/learn-more-about-who-art/ (accessed on 5 August 2020).
Lee, M.Y.; Choi, D.S.; Lee, M.K.; Lee, H.W.; Park, T.S.; Kim, D.M.; Chung, C.H.; Kim, D.K.; Kim, I.J.; Jang, H.C.;
et al. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal
insulin treatment: Randomized, parallel, open-label, active-controlled study. J. Korean Med. Sci. 2014, 29,
90â€“97. [CrossRef] [PubMed]
Vichayanrat, A.; Ploybutr, S.; Tunlakit, M.; Watanakejorn, P. Efficacy and safety of voglibose in comparison
with acarbose in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2002, 55, 99â€“103. [CrossRef]
Martin, A.E.; Montgomery, P.A. Acarbose: An alpha-glucosidase inhibitor. Am. J. Health-Syst. Pharm. AJHP
Off. J. Am. Soc. Health-Syst. Pharm. 1996, 53, 2277â€“2290. [CrossRef]
Dabhi, A.S.; Bhatt, N.R.; Shah, M.J. Voglibose: An alpha glucosidase inhibitor. J. C. Diagn. Res. JCDR 2013, 7,
3023â€“3027.
Wald, A. Sequential tests of statistical hypotheses. Ann. Math. Stat. 1945, 16, 117â€“186. [CrossRef]
Wald, A. Sequential Analysis. In Wald Sequential Analysis 1947; Jon Willey & Sons. Inc.: New York, NY,
USA, 1947.
Chan, C.L.; Rudrappa, S.; San Ang, P.; Li, S.C.; Evans, S.J. Detecting signals of disproportionate reporting
from singaporeâ€™s spontaneous adverse event reporting system: An application of the sequential probability
ratio test. Drug Saf. 2017, 40, 703â€“713. [CrossRef]
Chan, C.L.; Soh, S.; Tan, S.H.; Ang, P.S.; Rudrappa, S.; Li, S.C.; Evans, S.J. Quantitative data mining in signal
detection: The Singapore experience. Exp. Opin. Drug Saf. 2020, 19, 1â€“7. [CrossRef] [PubMed]
Kulldorff, M.; Davis, R.L.; Kolczak, M.; Lewis, E.; Lieu, T.; Platt, R. A maximized sequential probability ratio
test for drug and vaccine safety surveillance. Seq. Anal. 2011, 30, 58â€“78. [CrossRef]
Huang, L.; Zheng, D.; Zalkikar, J.; Tiwari, R. Zero-inflated poisson model based likelihood ratio test for drug
safety signal detection. Stat. Methods Med. Res. 2017, 26, 471â€“488. [CrossRef] [PubMed]
Â© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

